Summary

• CHD's MONI2 combines a washable sensor belt, patient application and clinical monitoring platform for high-risk pregnancies.
• Venture Kick support is reported at CHF150,000 cumulatively, although the programme's public company profile still records an earlier funding stage.
• Clinical validation, regulatory approval and integration into maternity services remain ahead of commercial medical use.

Swiss medical technology developer Connected Health Development (CHD) has secured reported cumulative support of CHF150,000 from Venture Kick to advance a wearable system intended to monitor high-risk pregnancies outside hospital settings.

The funding development, reported on 26 October, supports continued work on MONI2, a smart textile belt connected to patient and clinical software. CHD is developing the system to collect physiological information from pregnant women and their unborn babies, allowing clinicians to review selected measurements remotely.

Current reporting places total Venture Kick support at CHF150,000, approximately €160,000. That appears to represent progression through the programme’s funding stages rather than an entirely separate new investment of that amount. Venture Kick’s public company profile still records CHF50,000 from an earlier stage and has not been updated to reconcile the full total.

The company plans consumer and medical versions using the same underlying hardware, but MONI2 remains under development. Independent clinical performance results, completed medical regulatory clearance and evidence of routine healthcare deployment have not been published.

Textile sensors move monitoring outside hospitals

CHD is designing MONI2 around a washable belt containing sensors intended to collect maternal and fetal electrocardiogram signals, uterine contractions and information associated with fetal movement and position.

The physiological measurements would be transferred to digital applications, with pregnant women receiving basic indicators through a smartphone interface and healthcare professionals accessing more detailed information through a separate platform.

Such an arrangement could support selected monitoring activities between appointments, particularly where a pregnancy requires frequent clinical supervision but continuous hospital attendance is not otherwise necessary.

However, the ability to collect information remotely does not establish that a device can replace clinical examinations or established monitoring procedures. Healthcare professionals must determine which patients could use the system, which measurements are sufficiently reliable and how unexpected findings would be handled.

MONI2’s proposed predictive indicators introduce a further distinction between collecting physiological signals and interpreting them for clinical use. Detecting a potentially significant pattern requires evidence that the software can distinguish relevant changes from ordinary physiological variation and measurement errors.

False alarms may generate unnecessary appointments and anxiety, while missed warning signs could delay essential care. The balance between these outcomes must be evaluated in the population for which the product is intended.

Signal quality sets demanding requirements

Wearable medical sensors must operate under less controlled conditions than equipment used in a hospital examination room. Patients may move, change position or use the system incorrectly, while changes in sensor contact can introduce noise into the measurements.

Fetal electrical signals can also be difficult to distinguish from stronger maternal signals and interference arising from movement or surrounding equipment.

A clinically useful system must therefore demonstrate that it can collect and interpret appropriate information consistently, rather than simply produce recordings that appear plausible under favourable test conditions.

CHD’s proposed technology also needs to account for variation between patients. Anatomy, physiological characteristics and individual pregnancy conditions may affect both sensor performance and the interpretation of collected data.

Predictive models trained on limited samples can perform differently when introduced to a wider clinical population. Developers need to establish where a model performs reliably and identify circumstances in which it should not be used to support a particular decision.

The company has described early technical development and planned functional prototypes, but it has not disclosed prospective clinical trial results demonstrating the accuracy of its monitoring or prediction capabilities.

Validation will need to compare the system against relevant established methods and define what constitutes an acceptable level of performance for each intended use.

Consumer and medical products face different obligations

CHD plans to introduce consumer and medical versions of MONI2 using common hardware. That approach could allow the company to reuse engineering work, but the two products may face different requirements depending on their intended functions and the claims made about them.

A consumer product displaying general wellness information is not necessarily assessed in the same way as a medical device intended to support diagnosis or clinical management.

Medical deployment requires evidence appropriate to the intended clinical purpose, alongside controls covering product development, risk management, cybersecurity and the handling of sensitive patient information.

The proposed software platform will also need to integrate with maternity workflows. A continuous stream of measurements is useful only if healthcare professionals know who is responsible for reviewing it, how quickly information should be assessed and which results warrant intervention.

Monitoring outside hospital can reduce some travel requirements, but it may also create additional work if alerts require frequent investigation or patients need substantial technical assistance.

The economics of remote care consequently depend on the complete service, including devices, software, clinical oversight, maintenance and support.

Healthcare providers may also need to plan for interrupted connectivity, damaged equipment or situations in which a patient cannot obtain a reliable reading. A remote monitoring service must not create uncertainty about how care will continue when its technology is unavailable.

Funding supports validation rather than expansion

CHD was incorporated in Switzerland in February 2026 and operates from the Lausanne area. Its earlier Venture Kick support was intended to help develop functional prototypes, while the latest reported funding total reflects further progression through the startup support programme.

Venture Kick’s staged model ordinarily combines an initial award with subsequent financing that may take the form of convertible loans. The funding should not therefore be presented as equivalent to a single unrestricted equity investment.

CHD has described the programme’s support as part of its initial seed fundraising effort, with private investors and a foundation also involved in discussions or commitments. The company has not published a fully reconciled total for its wider financing round.

It has also outlined a commercial ambition to sell more than 30,000 monitoring kits and subscriptions over four years. That figure is a target, not a confirmed customer order book or evidence of established demand.

Medical providers considering the product would need evidence about its performance, regulatory position and contribution to clinical care before making substantial procurement commitments.

The distinction is important because remote patient monitoring depends on professional adoption as much as technical feasibility. A product may gather useful measurements but still encounter difficulties if it does not fit how healthcare teams organise appointments, respond to alerts and record clinical decisions.

CHD’s next milestones are technical validation, the completion of appropriate clinical evidence and clarification of the regulatory pathway for each version of MONI2.

The reported Venture Kick support provides additional development resources, while the practical value of the technology remains dependent on proving that reliable monitoring can be delivered outside hospital without introducing unacceptable clinical or operational risks.